Bloomberg Law
Dec. 14, 2022, 10:00 PM

Two Ebola Vaccines Provide Lasting Immune Response in Big Study

Immanual John Milton
Immanual John Milton
Bloomberg Editorial

Two shots that protect against Ebola virus yielded immune responses lasting for at least a year, according to a study suggesting they might keep the virus at bay for the long-term.

Researchers studied the vaccines, one from Merck & Co. and a two-dose regimen from Johnson & Johnson and Bavarian Nordic A/S, in 1400 adults and 1401 children enrolled from April to December 2018, according to a report from the Partnership for Research on Ebola Vaccinations research consortium. People responded to the shots within two weeks of receiving them, and the highest rate of response was achieved by the ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.